Logo

Cyntellect Wins $1.5M Phase II SBIR Grant to Continue Developing Applications for LEAP Technology

Sep 14, 2004

NEW YORK, Sept. 14 (GenomeWeb News) - Cyntellect has received around $1.5 million in a Phase II Small Business Innovative Research grant to continue developing RNA interference applications on its LEAP platform, the company said today.

 

Specifically, the money will help the privately held company pay for further development of its LEAP-enabled LaserFect technology for high-efficiency, low-toxicity delivery of siRNA into cells "that are typically refractory to standard transfection techniques."

 

The award comes 10 months after Cyntellect won $500,000 in a Phase II SBIR grant to develop the laser-based transfection technology, and the fifth the company has received since July 2003, RNAi News, GenomeWeb News' sister publication, reported in November.

Breaking News
The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.